Neurological Disorders, Corticosteroids, and Fracture Risk: Hiding in the Hindsight!
Amit Kapila, Aastha Takkar
Citation Information :
Kapila A, Takkar A. Neurological Disorders, Corticosteroids, and Fracture Risk: Hiding in the Hindsight!. J Postgrad Med Edu Res 2022; 56 (2):61-62.
Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112(5): 352–364. DOI: 10.7326/0003-4819-112-5-352
Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996;81(10):3441–3447. DOI: 10.1210/jcem.81.10.8855781
Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49(3):239–248. DOI: 10.1111/j.1365-4632.2009.04322.x
Naganathan V, Jones G, Nash P, et al. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 2000;160(19): 2917–2922. DOI: 10.1001/archinte.160.19.2917
Lloyd ME, Spector TD, Howard R. Osteoporosis in neurological disorders. J Neurol Neurosurg Psychiatry 2000;68(5):543–547. DOI: 10.1136/jnnp.68.5.543
Leonard H, Downs J, Jian L, et al. Valproate and risk of fracture in Rett syndrome. Arch Dis Child 2010;95(6):444–448. DOI: 10.1136/adc.2008.148932
Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62(11):1515–1526. DOI: 10.1002/acr.20295
